Biotechnology

Supreme Court Torches Prometheus Patents

Subscription Required

By James DeGraw | 4/5/12 2:24 PM |

After a unanimous decision rejecting patentability of laws of nature, without more, innovators may have to turn to other means to protect inventions, explains James DeGraw of Ropes & Gray.

Shedding Light on 'Prometheus'

Subscription Required

By Robin Cooper Feldman | 3/9/12 3:01 PM |

The upcoming Supreme Court decision will draw a boundary line between fact of nature and human invention, explains Robin Cooper Feldman of UC-Hastings.

sponsor spotlight

Path for Generics Open in Biotech

Subscription Required

By Siegfried J.W. Ruppert and Guy W. Chambers | 2/29/12 12:57 PM |

Recent FDA guidelines outline how competitors can establish their product as biosimilar to a branded one, explain Duane Morris attorneys.

Forecasting Forthcoming 'Biosimilar' Drug Regulations

Subscription Required

By Siegfried J.W. Ruppert and Guy W. Chambers | 8/30/11 4:54 PM |

By year's end, FDA will release rules controlling the approval process of large molecule generic drugs, explain Duane Morris attorneys.

sponsor spotlight

Patenting Personal Medicine Inventions

Subscription Required

By Michael Shuster and Pauline Farmer-Koppenol | 8/18/11 1:41 PM |

Federal Circuit held that DNA is patent-eligible subject matter with certain restrictions, but upcoming decisions could provide clarity and narrow the limitations, explain Fenwick & West attorneys.

The Pros and Cons of Gene Patents

Subscription Required

By Chester S. Chuang and Denys T. Lau | 12/17/10 11:40 AM |

As 'Myriad' heads to the Federal Circuit, many questions remain unsettled on the patentability of the human genome, explain professors Chester S. Chuang, pictured, and Denys T. Lau.